Skip to search formSkip to main contentSkip to account menu

indium In 111 ibritumomab tiuxetan

Known as: In 111 Ibritumomab Tiuxetan, In111 ibritumomab tiuxetan, Indium In-111 Ibritumomab Tiuxetan 
A radiolabeled monoclonal antibody that is used to detect certain types of B-cell non-Hodgkin lymphoma and is being studied in the detection of other… 
National Institutes of Health

Related topics

Related topics

2 relations
IDEC-In2B8/rituximabIDEC-In2B8/rituximab/yttrium Y 90 ibritumomab tiuxetan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Radioimmunotherapy in the Transplant Setting
High-dose chemotherapy (HDC) conditioning regimens with autologous stem cell transplantation (ASCT) or reduced intensity… 
2017
2017
Preliminary Experience of Yttrium-90 Ibritumomab Tiuxetan in Patients with Low-Grade B Cell Non-Hodgkin Lymphoma
Review
2016
Review
2016
After more than a decade of reatment experience , what have we learned ?
Non-Hodgkin’s lymphoma (NHL) comprises a clinically and biologically heterogeneous group of lymphoproliferative disorders… 
2013
2013
multicenter trial refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or
Review
2010
Review
2010
Handbook of therapeutic antibodies : technologies, emerging developments and approved therapeutics
Section I: Technologies Foreword A Greeting from the Editor PART 0: INTRODUCTION Therapeutic Antibodies - From Past to Future… 
2010
2010
Biodistribution and Radiation Dosimetry of 90Y-Ibritumomab-Tiuxetan Using 89Zr-Ibritumomab-Tiuxetan and Immuno-Pet in Patients with B-Cell Nhl
2001
2001
Ibritumomab Tiuxetan Radioimmunotherapy Is Safe and Well Tolerated in Patients With Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma
Ibritumomab tiuxetan (Zevalin) consists of an anti-CD20 murine IgG1 kappa monoclonal antibody covalently bound to tiuxetan (MX…